In Europe, the 2007-08 winter season was dominated by influenza virus A (H1N1) circulation through week 7, followed by influenza B virus from week 8 onward. Oseltamivir-resistant influenza viruses A (H1N1) (ORVs) with H275Y mutation in the neuraminidase emerged independently of drug use. By country, the proportion of ORVs ranged from 0% to 68%, with the highest proportion in Norway. The average weighted prevalence of ORVs across Europe increased gradually over time, from near 0 in week 40 of 2007 to 56% in week 19 of 2008 (mean 20%). Neuraminidase genes of ORVs possessing the H275Y substitution formed a homogeneous subgroup closely related to, but distinguishable from, those of oseltamivir-sensitive influenza viruses A (H1N1). Minor variants of ORVs emerged independently, indicating multiclonal ORVs. Overall, the clinical effect of ORVs in Europe, measured by influenza-like illness or acute respiratory infection, was unremarkable and consistent with normal seasonal activity.
Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007-08 Season / A. Meijer 1, A. Lackenby, O. Hungnes, B. Lina, S. van-der-Werf, B. Schweiger, M. Opp, J. Paget, J. van-de-Kassteele, A. Hay, M. Zambon, P. Lachner, T. Popow-Kraupp, R. Strauss, B. Brochier, M. Sabbe, I. Thomas, V. Casteren, F. Yane, T. Georgieva, M. Kojouharova, R. Kotseva, A. Kurchatova, B. Aleraj, V. Drazenovic, D. Bagatzouni-Pieridou, A. Elia, M. Havlickova, J. Kyncl, S. Glismann, A. Mazick, L. Nielsen, D.M. Fleming, A. Lackenby, J. Watson, M. Zambon, O. Sadikova, I. Sarv, T. Ziegler, J.M. Cohen, V. Enouf, B. Lina, A. Mosnier, M. Valette, S. van der Werf, U. Buchholz, W. Haas, B. Schweiger, A.G. Kossivakis, V. Kyriazopoulou-Dalaina, A. Mentis, G. Spala, G. Berencsi, A. Csohán, I. Jankovics, S. Coughlan, L. Domegan, M. Duffy, M. Joyce, J. O'Donnell, D. O'Flanagan, F. Ansaldi, P. Crovari, I. Donatelli, F. Pregliasco, R. Nikiforova, I. Van Velicko, N. Zamjatina, A. Griskevicius, N. Kupreviciene, G. Rimseliene, J. Mossong, M. Opp, C. Barbara, T. Melillo, A. Arkema, T. Meerhoff, W.J. Paget, K. van der Velden, F. Dijkstra, G. Donker, J.C. de Jong, A. Meijer, G. Rimmelzwaan, M. van der Sande, B. Wilbrink, P. Coyle, H. Kennedy, H. O'Neill, O. Hungnes, B. Iversen, L. Brydak, M. Romanowska, I.M. Falcão, J.M. Falcão, H. Rebelo de Andrade, V. Alexandrescu, E. Lupulescu, W. Carman, R. Gunson, J. Kean, J. Mcmenamin, N. Milic, J. Nedeljkovic, H. Blaskovicova, Z. Kristufkova, M. Sláciková, K. Prosenc, M. Socan, I. Casas, A. Larrrauri, S. de Mateo, R. Ortiz de Lejarazu, P. Pérez-Breña, T. Pumarola Suñé, T. Vega Alonso, M. Brytting, A. Linde, P. Penttinen, S. Rubinova, Y. Thomas, M. Witschi, N. Yilmaz, M. Aranova, A. Mironenko, A. Hay, R. Jones, D. Thomas. - In: EMERGING INFECTIOUS DISEASES. - ISSN 1080-6040. - 15:4(2009 Apr), pp. 552-560. [10.3201/eid1504.081280]
Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007-08 Season
I. DonatelliMembro del Collaboration Group
;F. PregliascoMembro del Collaboration Group
;
2009
Abstract
In Europe, the 2007-08 winter season was dominated by influenza virus A (H1N1) circulation through week 7, followed by influenza B virus from week 8 onward. Oseltamivir-resistant influenza viruses A (H1N1) (ORVs) with H275Y mutation in the neuraminidase emerged independently of drug use. By country, the proportion of ORVs ranged from 0% to 68%, with the highest proportion in Norway. The average weighted prevalence of ORVs across Europe increased gradually over time, from near 0 in week 40 of 2007 to 56% in week 19 of 2008 (mean 20%). Neuraminidase genes of ORVs possessing the H275Y substitution formed a homogeneous subgroup closely related to, but distinguishable from, those of oseltamivir-sensitive influenza viruses A (H1N1). Minor variants of ORVs emerged independently, indicating multiclonal ORVs. Overall, the clinical effect of ORVs in Europe, measured by influenza-like illness or acute respiratory infection, was unremarkable and consistent with normal seasonal activity.File | Dimensione | Formato | |
---|---|---|---|
08-1280.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
395.61 kB
Formato
Adobe PDF
|
395.61 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.